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bstract
Bone morphogenetic proteins (BMPs) are a family of potent, multifunctional growth factors belonging to transforming growth factor- (TGF-
). They are highly conservative in structures. Over 20 members of BMPs with varying functions such as embryogenesis, skeletal formation,
ematopoiesis and neurogenesis have been identified in human body. BMPs are unique growth factors that can induce the formation of bone tissue
ndividually. BMPs can induce the differentiation of bone marrow mesenchymal stem cells into osteoblastic lineage and promote the proliferation
f osteoblasts and chondrocytes. BMPs stimulate the target cells by specific membrane-bound receptors and signal transduced through mothers
gainst decapentaplegic (Smads) and mitogen activated protein kinase (MAPK) pathways. It has been demonstrated that BMP-2, BMP-4, BMP-6,
MP-7, and BMP-9 play an important role in bone formation. This article focuses on the molecular characterization of BMPs family members,
echanism of osteogenesis promotion, related signal pathways of osteogenic function, relationships between structure and osteogenetic activity,
nd the interactions among family members at bone formation.
 2015 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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It is estimated that there are 200 million patients with osteo-
orosis in the world, and that over 10 billion dollars have been
xpended on the medicines used for therapeutic treatment of
steoporosis. Milk has long been regarded as a good stimulator
or bone growth and development. In addition to containing
ich calcium (Ca2+), other functional components and multi-
le biologically active polypeptides from bovine milk protein
lso play important roles. In 1985, Snow Brand Milk Products
o., Ltd. in Japan firstly reported the role of milk basic proteins
n prevention of bone loss. Since then, a growing number of
undamental researches on the relationships between the bioac-
ive milk proteins and osteoporosis have increasingly drawn
idespread attentions.
Bone morphogenetic proteins (BMPs) are a group of bioac-
ive proteins that were firstly isolated from the extract of bone∗ Corresponding author at: School of Food Science and Engineering, Harbin
nstitute of Technology, Harbin 150090, PR China. Tel.: +86 15945192686;
ax: +86 451 86282906.
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atrix by Urist in 1965 [1]. Cell proliferation, differentiation
nd matrix biosynthesis during reconstruction process of human
one are coordinately regulated by multiple growth factors,
mong which, BMPs, as the important inducing factors during
mbryonic development, are the most closely related to osteoin-
uction. As of to date, BMPs are a group of the most well studied
unctional proteins that can be used to postpone or therapeutic
reatment of osteoporosis, which have provided important ref-
rences for a large number of researchers to explore the similar
echanisms of bioactive proteins from the milk.
.  General  outline  of  BMPs  family
.1.  Types  and  structural  characteristics
To date, over 20 BMPs family members have been recog-
ized. BMP-1, which is procollagen C proteinase containing 730
mino acid residues with rich cysteine residue, is a regulatory
actor for bone growth and belongs to the family of metallo-
roteinases. The remaining BMPs belong to the multifunctional
rowth factors, transforming growth factor (TGF-) superfamily
lsevier B.V. All rights reserved.
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2]. TGF-  superfamily mainly includes four sub-families [3],
.e. TGF-  subfamily, BMPs subfamily, growth and differentia-
ion factors (GDFs) subfamily, and activins/inhibins subfamily.
ased on the sequence homology and the known functions, BMP
amily members are generally classified into four categories:
MP-2/4, BMP-5/6/7/8a/8b, BMP-9/10 and BMP-12/13/14 [4].
The precursors of bone morphogenesis proteins, which con-
ain 400–500 amino acid residues, are consisted of three parts,
.e. the amino-terminal secretory signal peptide, the correctly
olding pro-domain and the carboxyl terminal (contains 100–125
mino acid residues) [5]. Arg-X-X-Arg sequence motif in the
ro-domain is hydrolyzed by serine proteinase to form the
arboxyl terminal mature protein [6]. The structures of BMP
amily members are highly conserved; the C-terminal of a large
ajority of the BMP family members contains seven cysteine
esidues, among which, cysteine residues form intra-chain disul-
de bonds, the other cysteine residue is involved in the formation
f a disulfide bond with cysteine residue in other polypeptide
hain, thus, linking two protein monomers into dimers with
iological activity. This typical local inter-polypeptide disul-
de bond is known as cysteine knot, which forms the core of
he monomer [7]. Because BMP-3 and BMP-15 do not contain
he seventh cysteine residue, their monomers have the biological
ctivity. Except for them, all the other BMP family members are
apable of forming either homodimers or heterodimers. The het-
rodimers of BMP-2/5, BMP-2/6, BMP-2/7 and BMP-4/7 have
een found both in  vitro  and in  vivo  and they are all the activated
actors playing more effective roles in signal pathway than their
orresponding homodimers do [8,9].
.2.  Biological  activities  of  BMPs
With the development of gene engineering technologies,
he biological activities of a part of the BMPs family mem-
ers have been known and confirmed. During the embryonic
evelopment, BMPs are involved in the regulation of neuro-
enesis and erythropoiesis and induction of metamerization.
fter birth, BMPs play important roles in maintaining bone
ass and can induce the directional differentiation of mes-
nchymal stem cells (MSCs) into osteoblasts and thus, increase
he number of mature osteoblasts and enhance the differenti-
tion capability of osteoblasts. BMPs confer their effects on
steoblasts through activating the membrane receptors of BMPs
nd their signal pathways [5]. Clinical studies have indicated
hat BMPs have functions of stimulating bone fracture healing,
ontrolling the formation of different morphological character-
stics of mammal bone system [10]. It has been confirmed that
he biological effects of various BMPs are different. Among
ver 20 BMPs family members, BMP-2, BMP-4, BMP-6, and
MP-9 play more important roles in ossification, of which, the
ffects of BMP-9 on ossification are the strongest, followed by
hose of BMP-2 and BMP-7 [11]. Binding of BMPs to their
orresponding receptors is needed for playing their biologi-
al roles. The receptors for BMPs are serine/threonine kinase
eceptors, which are consisted of extracellular region contain-
ng 10–12 cysteine reissues, a trans-membrane domain and a
erine/threonine kinase cytosolic domain. BMPs receptors are
a
i
5
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ivided into two subfamilies, type-I and type-II. There are five
ype-I BMP receptors including ALK1(Acvrl1), ALK2(ActRI),
LK3(BRIa), ALK4(ActrIb) and ALK6(BRIb); there are three
ype-II BMP receptors including BRII, ActRIIa and ActRIIb [7].
.3.  Signal  transduction  pathways  for  BMP-induced
steoinductive  differentiation
BMPs signal pathways include two regulatory pathways:
he classical Smads-dependent pathways and the non-classical
mads-independent mitogen activated protein kinase (MAPK)
athway.
The BMPs signal transduction is mainly mediated via  the
lassical BMPs–Receptor–Smads signal pathway [12]. Smads
an be divided into three categories: the first category can
ctivate the receptors of BMPs to regulate Smads (R-Smads),
ncluding Smad-1, Smad-5 and Smad-8; the second category is
o-mediator Smads (Co-Smads), i.e.  Smad-4; the third category
s the inhibitory Smads (I-Smads) including Smad-6 and Smad-
. Fig. 1 shows BMPs firstly bind to the pre-formed type-I and
ype-II receptor complexes, then type-II receptor is activated and
ubsequently phosphalyzates the GS-domain of type-I receptor.
fterwards the phosphorylated type-I receptor recognizes the
orresponding R-Smads within the cytoplasm and phosphory-
ates it. The phosphorylated R-Smads, in turn, form complex
ith Smad-4 and transport into nucleic where it cooperates
ith other transcriptional factor and accessory factors to direct
he transcription of the target genes and to fulfill their roles in
ifferentiation of osteoblasts [13,14].
BMPs bind with either type-I or type-II receptors to
orm homo-complex or hetero-complex, that can activate
MPs–MAPKs signal pathway, and in turn can transduce the
ignal into nuclei via  JNK-1 and 2/3, ERK1/2, NF-B and p38
ignal pathways where they regulate the expression of target
enes and play their biological roles. This signal transduction
athway plays important role in BMP-induced osteogenesis [7].
allea et al. [15] found that MAPK (Erk1/2) and p38 signal
athways play decisive roles in the induction of differentiation
f C2C12 cells into osteoblasts.
.  Molecular  characteristics  of  BMPs  family  members
nd their  roles  in  osteogenesis
It has been demonstrated that BMP-2, BMP-6 and BMP-9 are
he most potent BMP proteins involved in the induction of the
ifferentiation of osteogenic stem cells into osteoblasts. BMP-
 acts during the entire process of the induced differentiation
Fig. 2) [16].
.1.  BMP-2
The mature human BMP-2 is an acidic glycoprotein with
olecular weight of approximately 32 kDa. It contains 114mino acid residues, is rich in glutamate and can be dissolved
n neutral salt solution with an isoelectric point between 4.8 and
.1. There is certain inter-species homology of BMP-2 among
ovine, rabbit, mice and human. In 1999, Scheufler et al. [17]
J. Yang et al. / Food Science and Human Wellness 3 (2014) 127–135 129
Fig. 1. Classic BMPs signal transduction pathway.
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aFig. 2. Schematic diagram
btained the crystal structure of BMP-2 at 2.7 A˚ resolution via
-ray differentiation analysis. The structural basis of BMP-2
onomer is the three intra-chain disulfide bonds formed by six
amilial conserved cysteine residues. Human BMP-2 proprotein
ontains four glycosylation sites. Among which, one glycosyla-
ion site is present in the polypeptide chain of the mature BMP-2
18].
It has been demonstrated that in mouse osteoprogenitor cells
acking the expression of BMP-2, their abilities of prolifera-
ion and osteanagenesis into osteoblasts in the repaired site
re seriously defective [14,19]. Lacking of BMP-2 can retard
he transformation of osteoprogenitor cells into osteoblasts.
steoblasts are derived from the differentiation of multi-
otential mesenchymal cells [20]. BMP-2 plays a significant
ole in stimulating the differentiation of mesenchymal cells
nto osteoblasts through stimulating Smad signal pathway, reg-
lating the transcription of osteogenesis-related genes such as
LP, type-I collagen, osteocalcin, and bone sialoprotein genes.
hrough activating its corresponding Smad-1 and Runx-2,
MP-2 coordinately and/or independently regulates the expres-ion of the osteoblast-specific gene, Osterix. Runx-2 is an
mportant transcriptional factor involved in osteoblast differ-
ntiation and bone development and is also the target gene of
t
n
aP-induced osteogenesis.
leidocranial dysostosis and can directly regulate the expression
f osteocalcin [21]. Msx2 is the homeobox gene in osteoblast
nd its expression is regulated by BMP-2. It can stimulate the
ifferentiation of osteoblast and can also mediate the expression
f Osterix in mesenchymal cells independent of the regulation by
unx-2. As a target gene of Runx-2, Osterix can stimulate the
ifferentiation of osteoblast precursor into mature osteoblasts
22]. Thus, the regulation of Osterix expression by BMP-2 is
ediated via  two different transcriptional factors, Runx-2 and
sx-2.
In mice lacking the specific expression of BMP-2, not only
o their osteoblasts perform poor functions but also they have
he difficulty healing bone fracture when it happens [23]. When
he cells and molecules involved in normal healing process
re detected, the primary healing reactions take place. How-
ver, under the condition of lacking BMP-2, osteoblasts are not
ctivated. The normal control mice displayed strong periosteum-
ctivating reactions. It can form highly proliferating callus which
irectly form new bone tissue in the original fractured site
nd/or the fully defective sites. There are a few periosteum reac-
ions in BMP-2-lacking thigh-bone, which in turn form reactive
ew bone. However, the bridging callus is completely lacking
nd there is certain distance to the edge of the fractured bone
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ithout the support of the repaired tissues. Chandler et al.
23,24] thought that when BMP-2 was lacking, the healing
rocess of bone fracture also became slow. Compared with
ther BMPs, BMP-2 is mainly involved in the maintenance
f the dynamic balance of the newly formed bone tissue. The
MP-2-mediated signal transduction pathways are essential for
ndogenous repair of bone fracture.
.2.  BMP-4
BMP-4 is a secretory, hydrophobic and acidic glycoprotein.
he mature polypeptide of BMP-4 contains 116 amino acids
ith the molecular weight of approximately 30 kDa. Struc-
urally, BMP-4 is similar to BMP-2. There is 83% homology in
mino acid sequence between BMP-4 and BMP-2. Both BMP-4
nd BMP-2 form a subfamily of BMPs family [25,26]. There
re two forms of human BMP-4 [27,28]: one is expressed in the
ature placenta tissue and its protein precursor is consisted of
02 amino acid residues; the other form is expressed in osteosar-
oma and its protein precursor is consisted of 408 amino acid
esidues. As a member of BMPs family, the core of BMP-
 monomer is the familial conserved cysteine-knot structure.
here is a signal peptide region in the N-terminal of BMP-4.
t contains four possible N-linked glycosylation sites. Among
hich, three are located at the same location [29].
BMP-4 plays important roles in bone formation. During the
tage of bone formation, BMP-4 is the stimulating factor for the
ssification of the soft bone during the early stage [30]. Before
he formation of new soft bone and bone, within 6 h after bone
racture, BMP-4 appeased and is expressed in large quantity and
eached 10 times the base line value and then reduced to the base
ine value within 72 h after trauma [31]. BMP-4 was found in
esenchymal cells, soft bone cells, periosteum, bone marrow
avity and the muscle cells in the neighbor of the bone fracture
ite [32]. In contrast, BMP-2 was found only in bone. This indi-
ates that during the early stage BMP-4 may play a unique role
n healing bone fracture. In the parallel experiments with mice
acking the expression of BMP-4/BMP-7, X-ray differentiation
nalysis and histological measurement revealed that BMP-4 and
MP-7 did not have the same role as BMP-2 did in healing bone
racture during early stage [23,24].
BMP-4 may indirectly stimulate bone formation by inhib-
ting the osteoclastogenesis and thus, plays important role in
he process of healing bone fracture. Osteoprotegerin (OPG) is
n inhibitory factor of osteoclastogenesis [33]. As the soluble
eceptor of OPG ligand, OPG competitively binds to RANK
eceptor with its ligand, RANKL, thereby inhibiting the binding
f RANKL to RANK receptor. OPG inhibits osteoclastogenesis
y interrupting the signal transduction between stromal cell line
T2 and osteoprogenitor cells. It has been found that BMP-4
ignificantly increased the expression level of the soluble OPG
n mouse bone marrow stromal cell line ST2. However, under the
ame condition, it did not cause effect on the generation of OPG
igand in ST2 cell line [33]. Further study found that BMP-4
nduced OPG expression via  p38 MAPK signal pathway in ST2
ell line. BMP-4 can stimulate bone formation through cooper-
tion with vascular endothelial growth factor (VEGF). BMP-4
s
w
m
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as been demonstrated to cooperate with VEGF to stimulate the
ather of mesenchymal stem cells (MSCs), enhancing their sur-
ival capability and enlarging soft bone formation [34]. These
arly stage-actions and acceleration of soft bone absorption
nally lead to significant enhancement of bone formation and
one healing. The beneficial effects of the cooperation between
EGF and BMP-4 depend on the proper proportion between
EGF and BMP-4. Otherwise, they will cause harmful effects
n bone healing.
.3.  BMP-6
BMP-6 gene encodes a polypeptide containing 513 amino
cid residues, which include a N-terminal peptide with 23 amino
cid residues and a propeptide with 490 amino acid residues. The
ropeptide is hydrolyzed by protease to generate an acidic gly-
oprotein containing 139 amino acid residues with molecular
eight of approximately 15.6 kDa and an isoelectronic point of
.6. As a BMPs family member, BMP-6 contains seven abso-
utely conserved cysteine residues. BMP-6 has three potential
-linked glycosylation sites [35]. Based on their amino acid
equence homology, BMP-5, BMP-6, and BMP-7 form a sub-
amily of BMPs family. The biggest difference between the
tructure of BMP-6 and BMP-7 lies in that H3 histone helix
amino acid residues 65–73) in the crystal structure of BMP-
 is different from that of BMP-7 [36]. Although they share
igh homology, there is significant difference in their specificity
oward type-I receptor. More specifically, the type-I receptor of
MP-6 is mainly ALK-2. The affinity of BMP-6 for BRIa is
0 times as that of BMP-7 to BRIa. The signal transduction
f BMP-6-receptor complex is mainly mediated via  Smad-5
37]. Glycosylation of the recognition motif Asn-73 of BMP-6
s very important for recognition and binding of BMP-6 with
CVR1A. When the glycosyl chain in recognition motif is
efective, ACVR1A-mediated BMP-6 signal pathways would
e totally lost. The flexibility of BMP-6 and N-linked glyco-
ylation recognition motif likely plays important roles for the
pecific binding of BMP-6 to ACVR1 [38].
The in  vivo  experiments have indicated that BMP-6 can stim-
late heterotopic bone formation. The in  vitro  experiments have
emonstrated that BMP-6 can significantly stimulate the osteo-
enesis and differentiation of chondroblast and induction of
n vitro  osteogenesis [37]. BMP-6 can strongly induce the activ-
ties of alkaline phosphatase (ALP) in several osteoplast cell
ines including C2C12 cells, MC3T3 E cells, and ROB-C26 cells
37]. Mizrahi et al. [39] used BMP-6 and BMP-2 to induce the
n vitro  differentiation of mouse MSCs into osteoplasts. They
ound that in MSCs, the speed of BMP-6-mediated induction
f osteogenesis was faster than that of BMP-2 and the quan-
ity of osteogenesis was also higher than that of BMP-2. By
sing the recombinant Adenoviruses technology, Zachos et al.
40] transfected BMP-6 gene into osteogenic mesenchymal stem
ells (OMSCs) and found that after transfection, the expres-
ion levels of the indicators of osteogenesis in BMSCs cells
ere increased, the extracellular matrix was increased and the
ineralization was enhanced, indicating that BMP-6 can stim-
late the differentiation of BMSCs into osteoblasts. The signal
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athways involved in BMP-6-mediated induction of osteogene-
is of MSCs share many common properties with other BMPs
amily members, but it is controlled by Osterix (SP7) and the
xpression of BMP-6 is also selectively up-regulated by estro-
ens.
BMP-6 can induce the differentiation of MSCs into
steoblasts, enhances the expression of the indicators of osteo-
enesis, stimulate calcification of cellular matrix and thus, in
urn, is involved in osteogenesis and bone repair. BMP-6 also
as the function of inducing ectopic osteogenesis [41].
.4.  BMP-7
As the BMPs family members, based on their amino acid
equence homology, BMP-7, BMP-5, BMP-6 and BMP-8 form
 subfamily of BMPs family [42]. The proprotein of BMP-7 con-
ains 431 amino acid residues consisting of three parts including
 signal peptide, a leader peptide and a mature peptide. Within
he cells, BMP-7 is synthesized in the proprotein form, which
s then hydrolyzed by proteinase at its carboxyl-terminal into
ature BMP-7 protein containing 148 amino acid residues. The
ature protein is then secreted out the extracellular matrix [43].
he relative molecular mass of the mature BMP-7 is approx-
mately 15.6 kDa and contains three glycosylation sites. The
resence of leader peptide and correctness of the glycosylation
ites are of significance for the correct folding and secretion of
rotein molecules. They can also increase the solubility of BMP-
 [44]. They form a circular structure via  three bisulfide bonds
ys38–Cys104, Cys67–Cys136 and Cys71–Cys138. From the
ysteine knot, four anti-β-sheets form two finger-like structures,
hich are located in the other end of a-helix perpendicular to the
nger-like structure, and thus, form a hand-shape structure [45].
inkage by bisulfide bond formed via  –103rd cysteine in two
ature BMP-7 monomers into dimer with biological activity
isplay a butterfly-shaped, compacted stacking structure. BMP-
 can combine with other BMPs to form heterogeneous dimers
uch as BMP-2/7 and BMP-4/7. The biological activity of het-
rogeneous dimers is higher that of BMP-7 homodimer by 2–20
imes [46].
BMP-7 is a pleiotropic growth factor. It was recently found
hat BMP-7 was related to the differentiation of brown adipose
issue. BMP-7 receptor is the BMPs family receptor containing
erine–threonine kinase domain. It is presented in many tis-
ues throughout the human body. This may be the reason for
he pleiotropic functions of BMP-7 [47]. The study by Shen
t al. [48] revealed that addition of BMP-7 as supplement to the
hondrocyte-differentiation culture medium containing TGF-
3 stimulated the expression of mRNA and/or proteins of the
ndicators of chondrocytes such as COL2A1 (type-II collagen),
OL9A1 (type-IX collagen), COL10A1 (type-X collagen) and
OX9 and could enhance the deposit of extracellular matrix pro-
eins. BMP-7 can stimulate TGF-3-mediated differentiation of
hondrocytes but its action alone does not induce the differen-
iation of chondrocytes. TGF-3 can enhance the expression of
OMP and BGN  genes related to differentiation of chondrocytes
ut addition of BMP-7 down-regulated the expression of COMP
nd BGN  genes. It has been speculated that down-regulation
f
g
ian Wellness 3 (2014) 127–135 131
f BGN  gene could stimulate the differentiation of chondro-
ytes. Addition of BMP-7 into the standard culture medium
or chondrocytes could stimulate the expression of the key
ndicators including secreted phosphoprotein-1 (SPP1 or osteo-
ontin), bone gamma-carboxyglutamic acid-containing protein
BGLAP, osteocalcin), and SP7 (osterix transcription factor) and
ccelerate the mineralization process of MSCs matrix. The most
ensitive gene that is up-regulated by BMP-7 is SP7. It was
ecently found that SP7 could stimulate the differentiation of
steoplasts both in  vitro  and in  vivo. At the presence of BMP-7,
P7 could be stably expressed in large amount up to 14 days.
his may be the potential mechanism for BMP-7-mediated stim-
lation of differentiation of osteoplasts. Miyamoto et al. [49]
ound that combination of BMP-7 and TGF-1 can stimulate
he chondrification of mesenchymal stem cells.
BMP-7 plays a role in stimulation of expression of the
ubstances needed for induction of osteogenesis including
steogenin (DNA), collagen synthesis and protein deposit. Its
ajor biological functions is to induce the differentiation of
he hematoma swelling, undifferentiated MSCs surrounding the
one fracture site into chondrocytes, osteoclasts and new bone
ormation via  calcium deposit and stimulate repair of bone frac-
ure.
.5.  BMP-9
BMP-9 is also known as growth differentiation factor 2
GDF-2). The proprotein of BMP-9 contains 428 amino acid
esidues consisting of three parts including signal peptide, leader
eptide and mature peptide. Unlike other BMPs family mem-
ers, the mature BMP-9 still keep the N-terminal propeptide that
s usually cleaved before secretion. Cellular experiments have
emonstrated that this leader peptide has no effects on the func-
ion of BMP-9. In fact, it plays certain role in maintaining the
tability of the mature BMP-9 after secretion [50].
Currently, it has been demonstrated that BMP-9 can strongly
nduce the differentiation of osteoplasts both in  vitro  and in
ivo. BMP-9 was introduced and expressed in mesenchymal
ells C3H10T1/2 by using recombinant adenoviruses technol-
gy. It was found that the activity of alkaline phosphatase was
ncreased by 180 times at the 9th days. Similar results of increas-
ng the activity of alkaline phosphatase were also obtained in
steoprogenitor cells C2C12 and osteoclasts TE85 cells [51].
MP-9 can stimulate the expression of indicators of the later-
tage osteoclasts and induce the formation of trabecular bone
nd bone matrix. Its effects are better than those of BMP-2/7.
ther experiments using non-recombinant adenovirus infection
lso demonstrated that BMP-9 had the function of inducing dif-
erentiation of MSCs into osteoclasts. Sheyn et al. [52] used the
echnology of perforation of cells to introduce rhBMP-9 into the
eg muscle of the transgenic mice and found the formation of
one tissue. Using nucleofector transfection technology, Aslan
t al. [53] enabled hMSCs to acquire and express BMP-9 and
ound bone formation 4 weeks after transfection.
BMP-9 is the most potent cytokine in inducing osteo-
enesis among BMPs family members. However, very little
s known about the mechanisms underlying BMP-9-mediated
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steogenesis. The signal pathways involved in BMP-9-mediated
steogenic differentiation of MSCs into osteoclasts are partially
verlapped with the signal pathways for other BMPs family
embers but they also differ significantly. BMP-9 can simulta-
eously stimulate the activation of Smad-1/5/8, p38 and ERK1/2
n mesenchymal cells C3H10T1/2. Luther et al. [54] found that
ithin the classic BMPs–Smads signal pathway, BMP-9 sig-
al is transduced mainly via  type-I receptors ALK1 and ALK2
hile the signal transduction for the traditional BMP-2/4/6/7 is
ainly mediated via  ALK3 and ALK6. It has been demonstrated
hat when the inhibitor for p38 was added, the ability of BMP-9-
ediated induction of osteogenesis was inhibited whereas when
he inhibitor for ERK1/2 was added, BMP-9-mediated induc-
ion of osteogenesis was enhanced [55]. The effects of p38 and
RK1/2 on BMP-9 are just opposite but BMP-9 simultaneously
timulates the activation of both p38 and ERK1/2. The coupling
f BMP-9 with other signal pathways stimulates bone formation.
nt/-Catenin signal pathway, insulin growth factor (IGF) path-
ays, and vitamin-A-like (retinoid) pathways play an important
ole during the process of BMP-9-mediated osteogenesis.
Unlike the other members of BMPs family, extracellular
ntagonist, noggin, does not inhibit BMP-9 signal pathway, like
t does in inhibiting BMP-2/4/7 signal pathways. Moreover, for
MP-3, the generally accepted BMPs inhibitory factor, although
t can inhibit BMP-2/4/7-mediated osteogenesis, its inhibitory
ffects on BMP-9-mediated osteogenesis were very weak [56].
his indicates that BMP-9 may not follow the traditional BMPs-
ignal pathways to play its role but follows the other pathways
r bypass to regulate the expression of its downstream genes,
hich, in turn, induce bone formation.
.  Functional  interactions  among  BMPs  family
embers in osteogenesis
Each BMPs family member possesses important physiolog-
cal functions. Among these functional proteins, they do not
erform their role independently. There are synergies among
hese members; especially, there are significant interactions
etween BMP-1, BMP-3 and several BMPs family members.
.1.  Interactions  between  BMP-1  and  BMPs  family
embers
BMP-1 was initially co-isolated with BMP-2 and BMP-3
rom bovine bone extract that had the activities of inducing
oft-bone and bone and was so named. However, BMP-1 is
 zinc-containing metal protein containing 730 amino acid
esidues and is rich in cysteine. It is practically different from
ther TGF-  superfamily members.
In 1996, two groups of investigators indicated that BMP-1
ossess the activity of procollagen C proteases (pCP) and can
odify the C-terminal propeptide of the procollagen I–III [57].
y doing so, it can modify a large amount of proproteins into
ature proteins that possess certain functions during the process
f ECM formation and can activate a part of TGF-  super-
amily members, which, in turn, play certain roles during the
evelopmental process.
N
i
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BMP-1 is the prototype of a type of proteases with structurally
onserved domain. In mammals, there are four types of BMP-
/TLD-like proteases. They are BMP-1, mTLD, mTLD-1 and
TLD-2. BMP-1 is consisted of four parts including N-terminal
egion, astacen-like metalloproteinase region, carboxyl-terminal
omplement-uegf-BMP-1 and epidermal growth factor-like
EGF-like) domain. CUB domain is involved in mediating
rotein-protein interactions [58]. EGF-like domain combines
ith Ca2+ in some proteins [59]. However, the Ca2+-dependent
roteinase activities of BMP-1/TLD-like proteases do not
epend on Ca2+ but combine with EGF-like domain [60]. How-
ver, combination of EGF-like domain and Ca2+ enable a part
f BMP-1/TLD-like proteinase structure to become the rigid
tructure, and thus, affects their structural and functional prop-
rties. BMP-1 contains many asparagine-linked glycosylation
ites. Some of which are highly conserved among some BMPs
amily members. Blockage of all the glycosylation sites or the
lycosylation at three glycosylation sites within CUB region can
lock BMP-1 secretion. However, blockage of glycosylation at
ome individual glycosylation sites did not block BMP-1 secre-
ion but affected the thermal stability of BMP-1 and the level of
CP activity [60].
Current study has found that mTLD (BMP-1–3) circulates in
uman blood and is highly expressed in patients with acute bone
racture. Thus, it is speculated that the circulated BMP-1–3 may
lay important role in repairing bone fracture and is a new indi-
ator. The in  vivo  experiment has found that systemic injection of
ice with long bone fracture and of rabbits with serious regional
lnar deficiency with human recombinant BMPs-1–3 can stim-
late bone healing. In contrast, injection of specific polyclonal
ntibody and endogenous BMPs-1–3 led to delayed bone junc-
ion. The in  vitro  experiments found that BMPs-1–3 can enhance
he expression levels of type-I collagen and osteocalcin in osteo-
lasts MC3T3-E1 and stimulate the formation of mineralized
one knot of mesenchymal stem cells [61].
BMP-1/TLD-like proteinase can activate BMP-2/BMP-4 of
GF- superfamily. Noggin and Chordin are the major extracel-
ular antagonists for BMPs. Their affinities for BMP-2/BMP-4
re higher than for other BMPs and negatively regulate BMPs.
oggin/Chordin can bind to BMPs and shelter the receptor
inding sites in BMPs and thus, inhibit the activation of their
eceptors and the phosphorylation of their down-stream pro-
eins, which, in turn, inhibit them to play their biological
unctions. Noggin/Chordin are rich in cysteine residues and
hus, they can form typical “cysteine knot” structure. BMP-1
an cleave Noggin/Choggin into cysteine-rich peptide fragment,
hich can enable the release of BMPs from the complex state
f BMP-1-Noggin/Chordin and thus, relieve the inhibition on
ignal transduction pathways that stimulate BMPs. As a metal-
oproteinase, BMP-1 can inhibit the expression of low level of
oggin/Chordin proteins during the entire bone reconstitution
rocess and also inhibit paracrine cells and thus, inhibit the roles
f Noggin/Chordin in the tissues and prevent the expression of
oggin/Chordin in large scale [61].
Thus, BMP-1/TLD-like proteinase plays an important rolen regulation of TGF-  superfamily members, particularly in
egulation of BMP-2/BMP-4 signal pathways.
 Hum
3
B
o
p
a
B
s
i
p
s
A
w
t
s
d
m
l
a
m
g
b
f
m
[
B
o
i
i
p
p
b
o
s
3

b
t
l
t
s
W
t
o
d
f
d
b
b
i
i
[
u
i
s
o
f
i
4
f
u
d
t
m
g
B
o
a
T
t
t
T
i
p
b
(
w
A
p
a
l
g
f
L
p
s
s
t
t
O
t
b
a
t
t
t
g
sJ. Yang et al. / Food Science and
.2.  Interactions  between  BMP-3  and  other  members  of
MPs family
BMP-3, which was initially isolated and purified as
steogenin from bovine decalcified bone, is the major com-
onent of osteogenin. In decalcified bone, BMP-3 is the most
bundant BMP, accounting for approximately 65% of total
MPs. Similar to other BMPs family members, BMP-3 is a
ecretory protein. It is firstly synthesized as precursor contain-
ng 400–500 amino acid residues, including N-terminal signal
eptide which directs secretion, a functional pre-domain respon-
ible for the correct folding and a C-terminal mature peptide.
fter hydrolytic cleavage at the Arg-X-X-Arg sequence motif
ithin the functional pre-domain by proteinase, the mature pro-
ein with functional activities is secreted from the cells. The
tructural basis of each BMP-3 monomer is the three intra-chain
isulfide bonds formed by six conserved cysteine residues. Each
onomer contains four -chains that are folded into two fingers-
ike structures and a conserved -helix H3, giving BMP-3 dimer
 butterfly-like structure.
The initial study demonstrated that like other BMPs family
embers, BMP-3 possesses the functions of inducing osteo-
enesis. However, further study found that BMP-3 causes the
iological effects that are opposite those caused by other BMPs
amily members [62]. Targeted knocking out BMP-3 gene in
ouse cells led to the increased biomass of bone trabecular
63]. However, transgenic technology was used to over-express
MP-3 in mouse bone progenitor cells. It was found that the
steogenesis activity of BMP-2 and BMP-4 in all cells was
nhibited and led to auto bone fracture in mice. BMP-3 also
nhibits the expression of the indicators of osteogenesis in osteo-
lasts after being treated with BMPs. This indicates that BMP-3
lays a role in negative regulation of bone metabolism.
It has been found that in adult bone, the osteoplasts and
one cells are the major sources of BMP-3. BMP-3 inhibits the
steogenic activities of BMPs via  three ways:
Firstly, unlike other BMPs family members that mediate the
ignal transduction via  BMPs/Smads signal pathways, BMP-
 mediates intracellular signal transduction mainly via  TGF-
 signal pathway. Smad-4 is a down-stream factor needed for
oth BMP-3 and BMPs to individually transduce their signals
o down-stream proteins. The presence of Smad-4 in cells is
imited. BMP-3 and BMPs competitively bind to Smad-4 and
hus, restrict the output of BMPs signals [64].
Secondly, as ligands, BMPs need to bind to their corre-
ponding type-I or type-II receptors during signal transduction.
hen signals are transduced into cells, BMP-3 and BMP-2 bind
o type-II receptor ActRIIb while receptor ActRIIb can bind
nly to either BMP-3 or BMP-2 to form complex and trans-
uce signals to the down-stream factors. The affinity of BMP-3
or ActRIIb is 30 times that of BMP-2 for ActRIIb. Allen-
orph et al. [36] further confirmed that the specificity for the
inding of BMP-3 to ActRIIb is controlled by the interaction
etween Lys-30 residue in BMP-3 and glutamate-76 residues
n ActRIIb. This will reduce the quantity of ActRIIb for bind-
ng of BMP-2. Thus, BMP-3 causes antagonism for BMP-2
65].
c
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Thirdly, current study has demonstrated that BMP-3 can stim-
late the proliferation of mesenchymal stem cells and plays
mportant role in the differentiation process of mesenchymal
tem cells into adipocytes [66].
As the result of the inhibition effect of BMP-3 on the
steogenic activities of BMPs, it can cause inhibition on the dif-
erentiation of osteoplasts. Thus, BMP-3 is a negative regulator
n bone metabolism.
.  Inspiration  of  the  studies  on  BMPs  for  exploration  of
ood-derived  bioactive  proteins  (peptides)
To date, many proteins that possess the activities of stim-
lating osteogenesis have been found. However, there are
ifferences between the degree of awareness and exploration on
hem. As mentioned above, as the important TGF-  superfamily
embers, BMPs possess high efficiency in stimulating osteo-
enesis. Among them, BMP-1, BMP-2, BMP-4, BMP-7 and
MP-9 have been relatively well studied. The common features
f food-derived bioactive peptides and BMPs family members
re that they all possess the activity of stimulating osteogenesis.
hen, are there any structural similarities between them? And are
here any common properties in their protein sequences and spa-
ial structures among these osteogenesis-stimulating proteins?
hese questions are worthy for further study.
The high mobility group (HMG) proteins and Kininogen1/2
n milk can stimulate the proliferation of osteoplasts. Cysteine
rotease inhibitors C (Cystatin C) and angiogenin can inhibit the
one absorption caused by osteoclasts [67,68]. Milk osteopontin
OPN) plays important roles in bone metabolism [69]. It interacts
ith integrin v3 receptor via  its specific conserved Arg-Gly-
sp sequence motif and plays important role in regulation of the
roliferation and differentiation and their activities of osteoclast
nd osteoplasts [70,71]. It has been reported that insulin-
ike growth factor-1 (IGF-1), recombinant human transforming
rowth factor-1 (TGF-1), and vascular endothelial growth
actor (VEGF), etc. possess osteogenesis-stimulating activities.
actoferrin is currently the most frequently reported bioactive
eptide. Especially, the newest finding on its osteogenesis-
timulating activities has drawn increasingly attentions.
It is well known that in the studies on protein
tructure–activity relationships, the most basic requirement is
o firstly obtain the bioactive protein with high purity and then
o conduct research with different means and in different aspects.
ne relatively important way is to directly cleave (separate) the
arget protein into several structural units and fragments with
iochemical methods and then conduct structural measurement
nd functional experiments, respectively, and finally determine
he structure–activity relationships as a whole. Another rela-
ively new way is to use bioinformatics methods to compare
he similarities in protein sequences and structures of the tar-
et proteins with those of many other proteins that have the
imilar functions, especially the structures of the known active
enter. Finally, the data analysis and reorganization are con-
ucted to reveal the structure–activity relations of the target
roteins. The third way is to conduct point mutations on the key
mino acid residues or region based on protein sequences and/or
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hree-dimensional structures to determine the structure–activity
elationships of the target proteins with molecular biology meth-
ds [72]. Among three methods, the first two are commonly
sed by the researchers in the fields of nutrition and food sci-
nces and also have obtained good results [73]. The third method
s commonly used in researches on molecular biology, which
an provide detail information about the structure–activity rela-
ionships but it is time-consuming, tidier and high-cost. It is
sually used when the first two methods are failed or is used for
onfirming certain hypothesis.
In summary, for the studies on structure–activity relationships
f food-derived bioactive proteins (peptides), especially the
tudies on their structure–activity relationships in ontogenesis-
timulating activities, we can use the mechanisms of BMPs
ntogenesis as the basis to conduct research using biochemical
nd bioinformatics technologies. These approaches will allow us
o test the scientific hypothesis with more clear directionality and
o determine the structures of food-derived bioactive proteins
peptides) and their relationships in ontogenesis-stimulating
ctivities. These studies will eventually provide the theoretical
asis for development and exploration of food-derived bioactive
roteins (peptides) for practical production.
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